Americans Set to Receive Direct Payments from Generic Drug Settlement
Sun Pharmaceuticals and Taro Pharmaceuticals have agreed to pay $85 million to settle antitrust claims alleging they conspired to raise fixed prices on generic drugs. The settlement marks a victory for consumers who paid higher prices for medications as a result of the alleged price-fixing scheme.
To qualify for a direct payment, Americans must have purchased specific generic drugs provided by Sun Pharmaceuticals or Taro Pharmaceuticals within the period of May 1, 2009, to December 31, 2019. Additionally, they should not have purchased the drugs from Walgreens or CVS.
Affected individuals are urged to act fast and file their claim form before the deadline of May 6, 2024. Claim forms can be downloaded from the settlement website. Those who already received a claim form by mail may not need to provide proof of purchase.
The distribution of payments will vary based on the amount of eligible drug purchases included per applicant. The estimated amount of individual payments has not yet been determined, but it is expected that claimants will receive a substantial portion of the $85 million settlement.
This settlement serves as a reminder of the importance of class action lawsuits in holding corporations accountable for their actions. By banding together, consumers can seek justice and recover damages for wrongdoing that impacts a large group of people.
